

JOHCM Global Select Fund

Fund overview

- The Fund aims to generate long-term total returns through active management of a concentrated portfolio of listed global equities securities
- Fund managers Christopher Lees and Nudgem Richyal have a growth at a reasonable price (GARP) philosophy and aim for consistency of returns by exploiting multiple market anomalies/ inefficiencies
- They believe that they increase the probability of finding attractive stocks by looking where traditional growth investors do not look: stocks early in the growth life-cycle, off the beaten track, or in out of favour areas of the stock market that are recovering
- SFDR classification: Article 8. Please click [here](#) for further details
- Benchmark: MSCI AC World Index
- The Fund is managed on an 'unconstrained basis' with no restrictions in terms of regional or sector allocation versus its benchmark
- Please see the [Prospectus/KIID/KID](#) for further information. Please ensure you read and understand these documents before making an investment and wherever possible obtain professional advice

Share class: A GBP Class

ISIN: IE00B3DBRN27

Fund details

Fund size	GBP 1.23bn
Strategy size	GBP 2.58bn
Launch date	30 September 2008
Benchmark	MSCI AC World NR (12pm adjusted)
No. of holdings	40
Domicile	Ireland
Fund structure	UCITS
Tax status	UK reporting status
Denominations	GBP, EUR, USD
Valuation point	12pm Dublin time
SFDR	Article 8

Total strategy assets updated quarterly and shown as at 31 December 2023.


Fund managers



Christopher Lees

Senior Fund Manager

Chris has managed the Fund since launch. He joined JOHCM in 2008 and has 34 years of industry experience.




Nudgem Richyal

Senior Fund Manager

Nudgem has managed the Fund since launch. He joined JOHCM in 2008 and has 24 years of industry experience.

Performance highlights

Return since launch (%)



Return history

	1m	3m	1yr	3yr	5yr	10yr	SL	Annualised*
A GBP Class	7.72	16.86	16.42	9.92	59.85	157.57	407.65	11.11
Benchmark	3.23	9.83	17.09	33.21	72.31	194.68	408.91	11.13
Quartile**	1	1	2	3	2	2	1	-

Discrete 12 month performance to end of February

	02.24	02.23	02.22	02.21	02.20	02.19	02.18	02.17	02.16	02.15
A GBP Class	16.42	-9.73	4.59	36.43	6.59	2.60	13.05	25.71	-8.17	20.34

Past performance is no guarantee of future performance.

The value of an investment and the income from it can fall as well as rise as a result of market and currency fluctuations and you may not get back the amount originally invested. For further information on risks please refer to the Fund's KIID/KID and/or the Prospectus. Investing in companies in emerging markets involves higher risk than investing in established economies or securities markets. Emerging Markets may have less stable legal and political systems, which could affect the safe-keeping or value of assets. The Fund's investment include shares in small-cap companies and these tend to be traded less frequently and in lower volumes than larger companies making them potentially less liquid and more volatile.

NAV of Share Class A in GBP, net income reinvested, net of fees. The A GBP Class was launched on 30 September 2008. Performance of other share classes may vary and is available on request.

*Annualised since launch. **Refers to the fund's ranking in a peer group of funds made up from all funds classified as Global Equity by either the Investment Association (IA) or Lipper Global. Funds included may be domiciled in the UK, Ireland, or Luxembourg.

Contact details

Dealing & Investing
+353 1 434 5239

Fax
+353 1 553 9436

Email: JOH_Offshore_TAQueries@ntrs.com



Portfolio analysis (%)

Data as at 29 February 2024

Top 10 holdings

	Absolute	Relative
Microsoft	3.3	-0.9
Zealand Pharma	3.0	3.0
CRH	2.9	2.8
Amazon	2.8	0.4
Broadcom	2.7	1.9
Intercontinental Exchange	2.6	2.5
B3	2.5	2.5
Alphabet	2.5	0.3
SK hynix	2.5	2.4
Linde	2.5	2.2
Total	27.3	

Sector breakdown

	Absolute	Relative
Health Care	17.1	5.9
Information Technology	29.2	5.3
Materials	7.4	3.3
Financials	18.9	3.0
Consumer Discretionary	9.4	-1.7
Energy	2.3	-2.0
Industrials	8.7	-2.1
Real Estate	0.0	-2.2
Utilities	0.0	-2.4
Communication Services	2.5	-5.0
Consumer Staples	0.0	-6.5
Cash	4.3	4.3

Active positions

Top 5	Relative
Zealand Pharma	3.0
CRH	2.8
B3	2.5
Intercontinental Exchange	2.5
Nu Holdings	2.4
Bottom 5	Relative
Apple	-3.8
Nvidia	-2.8
Meta	-1.6
Microsoft	-0.9
Tesla	-0.8

Regional breakdown

	Absolute	Relative
Emerging Latin America	7.1	6.2
Japan	6.7	1.1
Pacific ex Japan	2.0	-0.5
Emerging Asia	7.0	-0.9
United Kingdom	2.2	-1.0
Emerging Europe & Middle East	0.0	-1.3
Europe ex UK	10.4	-1.7
North America	60.2	-6.3
Cash	4.3	4.3

Market cap breakdown

	Absolute	Relative
Large (>USD 10bn)	79.4	-15.7
Mid (USD 1 - 10bn)	16.3	11.4
Cash	4.3	4.3

Large = >USD 10bn, Mid = USD 1bn to USD 10bn, Small = <USD 1bn

Attribution & contribution (%)

Stock attribution

Top contributors	Relative return
Viking Therapeutics	3.86
Zealand Pharma	0.92
Nu Holdings	0.59
CRH	0.34
Daifuku	0.30
Top detractors	
Nvidia	-0.55
AP Memory	-0.50
Dynatrace	-0.44
Sony	-0.43
Fortescue Metals	-0.38

Sector attribution*

	Relative return
Health Care	4.95
Financials	0.61
Energy	0.26
Materials	0.23
Industrials	0.22
Consumer Staples	0.17
Utilities	0.12
Real Estate	0.06
Communication Services	-0.16
Consumer Discretionary	-1.03
Information Technology	-1.68

*Excludes cash

Please note that due to rounding breakdowns may not add to 100.00%. All Attribution figures are as at end of day and are calculated on a gross basis.



Fund manager's commentary

- We have outperformed year-to-date, mainly due to positive stock selection in healthcare, materials and financials
- The momentum signals we've seen recently suggest that small and mid-caps will see strong gains and outperform over the next six to 12 months
- We are positioned for 2024 being a vice versa of 2023 in several ways, with better performance from 2023's laggards such as small and mid-caps, emerging markets and Japanese equities

We have outperformed year-to-date, mainly due to positive stock selection in healthcare (*Viking Therapeutics, Zealand Pharma*), materials (*CRH, Linde*) and financials (*Nu Holdings, Bank Mandiri*). This was slightly offset by negative stock selection in technology (*Adobe* reported disappointing earnings guidance and was sold) and industrials (*GXO* reported disappointing earnings guidance and is under review).

So far in 2024, the Magnificent 7 has shrunk to the Fabulous 5 (*Nvidia, Amazon, Microsoft, Meta* and *Alphabet*) because the Dire Duo (*Tesla* and *Apple*, whom we do not own) reported disappointing earnings guidance and underperformed. *Alphabet* might be the next one to stumble; we are monitoring it closely.

We think the biotech sector is in a new bull market. Last month we mentioned our high conviction view that Biotech had bottomed in Q4 of 2023 driven by a whole host of innovation coming to fruition. In February, some of our big winners were names in the cardio-metabolism area that we highlighted, namely *Zealand Pharma* and *Viking Therapeutics* as both reported excellent results from trials of their next generation anti-obesity drugs.

We think the Japanese equity market has also started a new bull market, buoyed by the push for structural reforms at the corporate level. In February we purchased *Recruit Holdings* to go overweight Japan for the first time in a long time. This was funded by the sale of *Abobe*, whose business model might be eroded as OpenAI invades its turf with text-to-video creation tools.

Our 2024 scenario analysis and outlook are 80% bullish and 20% bearish. Short term reasons to be bearish include the ongoing potential for a recession and geopolitical tensions. Medium term reasons to be bullish include the Fed regaining credibility with inflation and interest rates stabilising and an AI productivity boost.

Scenario 1 = 10% probability that US Magnificent Seven leadership continues. New bull market leadership is not usually the old bull market leadership, but several things are 'different this time,' eg AI, Cold War 2.0

Scenario 2 = 70% probability of broadening bull market. US interest rates stabilising or China (the world's second largest economy) stabilising are catalysts for this positive outcome

Scenario 3 = 20% probability of bear market or zig-zag. Resurgent inflation and interest rates rising, or geopolitical/Middle-Eastern escalations are catalysts for this negative outcome

The momentum signals we've seen recently suggest that small and mid-caps will see strong gains and outperform over the next six to 12 months, even if the overall indices struggle if the mega-caps that dominate these indices underperform after their exceptional outperformance in 2023. However, just because small and mid-caps look poised to outperform doesn't mean there isn't a place for some mega-caps with positive earnings revisions in the portfolio, particularly those exposed to the mega-trends of AI and anti-obesity drugs.

We are positioned for 2024 probably being a vice versa of 2023 in several ways, with better performance from 2023's laggards such as small and mid-caps, emerging markets and Japanese equities. As at the end of February, the portfolio is underweight European equities and neutral to overweight USA, Japan and Asia/Emerging Markets.

Our top down scorecard shows several important changes year-to-date: the technology sector has become significantly overvalued but still has good fundamentals and trend. Biotech is starting a new uptrend within the health care sector, and the new obesity drugs success is becoming bad news for the consumer staples sector, which is now our largest underweight position in the fund, i.e. less food & beverage consumption.

Performance over 1 month	%
Fund - A GBP Class	7.72
Benchmark	3.23

Statistics

	Annualised since launch
Active share* (%)	86.29
Fund volatility (%)	17.80
Benchmark volatility (%)	16.22
Alpha	0.14
R squared	0.82
Correlation	0.90
Tracking error (%)	7.58
Information ratio	0.00
Sharpe ratio	0.57

Data calculated weekly.

*The proportion of stock holdings in a fund's composition is different from the composition found in its benchmark. The greater the difference between the composition of the fund and its benchmark, the greater the active share.

Fund awards & ratings



Ratings and awards are as at 31 January 2024. © 2024 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results. For more detailed information about Morningstar's Medalist Rating, including its methodology, please see <https://shareholders.morningstar.com/investor-relations/governance/Compliance--Disclosure/default.aspx>

Country registration

	A GBP	B GBP	A EUR	B EUR	A USD	B USD
Austria	✓	✓	✓	✓	✓	✓
Denmark	✓	✓	✓	✓	✓	✓
Finland	✓	✓	✓	✓	✓	✓
France	✓	✓	✓	✓	✓	✓
Germany	✓	✓	✓	✓	✓	✓
Ireland	✓	✓	✓	✓	✓	✓
Italy	✗	✗	✗	✓	✓	✗
Jersey	✓	✓	✓	✓	✓	✓
Lithuania	✗	✗	✓	✓	✓	✓
Luxembourg	✓	✓	✓	✓	✓	✓
Netherlands	✓	✓	✓	✓	✓	✓
Norway	✓	✓	✓	✓	✓	✓
Singapore	✓	✓	✓	✓	✓	✓
Spain	✓	✓	✓	✓	✓	✓
Sweden	✓	✓	✓	✓	✓	✓
Switzerland	✓	✓	✓	✓	✓	✓
UK	✓	✓	✓	✓	✓	✓

Regulatory documents

English language KIIDs can be found on our website at www.johcm.com

Foreign language versions are available on request by calling +44 (0) 20 7747 5646

Share class details (Further details on additional share classes are available on request)

	ISIN	SEDOL	Bloomberg	WKN	Initial charge	Annual charge	Ongoing charge	Minimum investment*
A GBP Class	IE00B3DBRN27	B3DBRN2	JHGLSIG ID	A0RCWM	Up to 5%	0.75%	0.78%	£1,000
B GBP Class	IE00B3DBRL03	B3DBRL0	JHGLSRG ID	A0RFHR	Up to 5%	1.498%	1.53%	£1,000

Performance fee: A performance fee of 15% is payable on the excess if the NAV outperforms the Index Adjusted NAV (as defined in the Fund supplement) on an annual basis. The calculation is performed daily. Any underperformance is carried forward.

Ongoing Charge is as at 31 December 2023.

*Other currency equivalents apply.

Important information

Professional investors only.

Issued and approved in the UK by J O Hambro Capital Management Limited ("JOHCM") which is authorised and regulated by the Financial Conduct Authority. Registered office: Level 3, 1 St James's Market, London SW1Y 4AH. Issued in the European Union by Perpetual Investment Services Europe Limited ("PISEL") which is authorised by the Central Bank of Ireland. Registered office: 24 Fitzwilliam Place, Dublin 2, Ireland D02 T296. References to "JOHCM" below are to either JOHCM or PISEL as the context requires. Perpetual Group is a trading name of JOHCM and PISEL.

This is a marketing communication. Please refer to the fund prospectus and to the KIID / KID before making any final investment decisions.

These documents are available in English at www.johcm.com, and available from PISEL, or (for UK investors) JOHCM, at the addresses set out above.

Information on the rights of investors can be found [here](#)

The distribution of this document in jurisdictions other than those referred to above may be restricted by law ("Restricted Jurisdictions"). Therefore this document is not intended for distribution in any Restricted Jurisdiction and should not be passed on or copied to any person in such a jurisdiction.

The registrations of the funds described in this document may be terminated by JOHCM at its discretion from time to time.

The investment promoted concerns the acquisition of shares in a fund and not the underlying assets.

Past performance is no guarantee of future performance. The value of an investment and the income from it can fall as well as rise as a result of market and currency fluctuations and you may not get back the amount originally invested.

Investing in companies in emerging markets involves higher risk than investing in established economies or securities markets. Emerging Markets may have less stable legal and political systems, which could affect the safe keeping or value of assets.

Investments include shares in small cap companies and these tend to be traded less frequently and in lower volumes than larger companies making them potentially less liquid and more volatile.

The information contained herein including any expression of opinion is for information purposes only and is given on the understanding that it is not a recommendation.

The information in this document does not constitute, or form part of, any offer to sell or issue, or any solicitation of an offer to purchase or subscribe for any funds described in this document; nor shall this document, or any part of it, or the fact of its distribution form the basis of, or be relied on, in connection with any contract.

Telephone calls to and from JOHCM and PISEL may be recorded. Information on how personal data is handled can be found in the JOHCM Privacy Statement on its website: www.johcm.com.

J O Hambro® and JOHCM® are registered trademarks of JOHCM.

Sources: JOHCM/Lipper/MSCI Group (unless otherwise stated).

Certain information contained herein (the "Information") is sourced from/copyright of MSCI Inc., MSCI ESG Research LLC, or their affiliates ("MSCI"), or information providers (together the "MSCI Parties") and may have been used to calculate scores, signals, or other indicators. The Information is for internal use only and may not be reproduced or disseminated in whole or part without prior written permission. The Information may not be used for, nor does it constitute, an offer to buy or sell, or a promotion or recommendation of, any security, financial instrument or product, trading strategy, or index, nor should it be taken as an indication or guarantee of any future performance. Some funds may be based on or linked to MSCI indexes, and MSCI may be compensated based on the fund's assets under management or other measures. MSCI has established an information barrier between index research and certain Information. None of the Information in and of itself can be used to determine which securities to buy or sell or when to buy or sell them. The Information is provided "as is" and the user assumes the entire risk of any use it may make or permit to be made of the Information. No MSCI Party warrants or guarantees the originality, accuracy and/or completeness of the Information and each expressly disclaims all express or implied warranties. No MSCI Party shall have any liability for any errors or omissions in connection with any Information herein, or any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.